Is Eli Lilly and Company (LLY) a Good Buy in 2026? Complete Investment Analysis
Quick Answer
In July 2026, Eli Lilly and Company (LLY) remains a Buy for growth-oriented investors, though it requires a stomach for premium valuations. The company has cemented its position as the largest healthcare company in the world by market capitalization, driven by the unprecedented success of its GLP-1 franchise (Mounjaro and Zepbound). With Q1 2026 revenue surging 56% year-over-year to $19.8 billion and full-year guidance raised to $85–$87 billion, Lilly's fundamentals are exceptionally strong. While the stock trades at a premium forward P/E of 33.4x, its PEG ratio of 1.57 indicates that this valuation is largely justified by its explosive earnings growth. Investors should view LLY as a core healthcare holding, though they must be mindful that the stock is priced for flawless execution.
Current Stock Price & Valuation
As of late July 2026, Eli Lilly's stock is trading near the $1,196.00 mark, representing a massive run-up over the past year Goldman Sachs says one number will move Eli Lilly stock - TheStreet. The stock has climbed approximately 11% year-to-date after recovering from a spring dip, and sits just below its 52-week high of $1,249.45 Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher - 24/7 Wall St..
From a valuation standpoint, Eli Lilly commands a premium multiple that reflects its market dominance:
- Trailing P/E: ~42x Eli Lilly (LLY) intrinsic value Analysis by StockOracle™
- Forward P/E: 33.4x Should You Buy Eli Lilly Stock? Here's My Honest Take. | The Motley Fool
- PEG Ratio: 1.57 Should You Buy Eli Lilly Stock? Here's My Honest Take. | The Motley Fool
To put this into perspective, competitor Novo Nordisk trades at a forward P/E of roughly 15x, but Novo's recent quarterly revenue grew at only 24% compared to Lilly's 55.5% Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher - 24/7 Wall St.. Similarly, Merck trades at a forward P/E near 24x with a sluggish 4.9% growth rate. Lilly's premium is a direct reflection of its superior growth trajectory.
Detailed Analysis
Revenue and Earnings Growth Trends
Eli Lilly's financial performance in 2026 has been nothing short of historic. Over the last twelve months (LTM) ending in late 2026, the company generated a staggering $86.46 billion in total revenues and $27.58 billion in consolidated net income, translating to a diluted EPS of $30.81 LLY (NYSE): Income statement | Fiscal.ai.
The primary engine of this growth is the GLP-1 franchise. In Q1 2026 alone, Mounjaro and Zepbound combined for $12.8 billion in revenue, up from $6.1 billion in the same quarter the previous year Eli Lilly (LLY) intrinsic value Analysis by StockOracle™. Mounjaro sales specifically jumped 125% year-over-year to $8.7 billion Should You Buy Eli Lilly Stock? Here's My Honest Take. | The Motley Fool.
Competitive Position and Pipeline
Beyond weight loss and diabetes, Lilly is aggressively expanding its moat. The company is making significant strides in the Alzheimer's space with its amyloid-targeting monoclonal antibody, Kisunla. Recent data presented at the 2026 Alzheimer’s Association International Conference in London aims to solidify Kisunla's competitive standing in a market historically plagued by diagnosis bottlenecks Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades - Benzinga.
Furthermore, Lilly has bolstered its pipeline through strategic acquisitions, including Ajax Therapeutics, Centessa Pharmaceuticals, 4E Therapeutics, and Kelonia Therapeutics Should You Buy Eli Lilly Stock? Here's My Honest Take. | The Motley Fool.
Analyst Price Targets and Ratings
Wall Street remains overwhelmingly bullish on LLY in July 2026. Following recent data releases and earnings beats, several major firms have upgraded their price targets:
- Truist Securities: Buy, $1,370 target Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades - Benzinga
- Morgan Stanley: Overweight, $1,347 target Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades - Benzinga
- BofA Securities: Buy, $1,334 target Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades - Benzinga
- Goldman Sachs: Buy, $1,283 target Goldman Sachs says one number will move Eli Lilly stock - TheStreet
Bull Case
The bull case for Eli Lilly rests on its undisputed leadership in the GLP-1 market, which analysts project could reach $150 billion by 2035 Should You Buy Eli Lilly Stock? Here's My Honest Take. | The Motley Fool. Management's confidence is palpable; they recently raised their full-year 2026 revenue outlook to $85–$87 billion Eli Lilly (LLY) Stock Remains a Buy after Q2 | Markets Insider.
Lilly is not just growing; it is accelerating. A 56% year-over-year revenue jump for a company of this size is virtually unheard of in the pharmaceutical sector. With Medicare's new GLP-1 Bridge program bringing Zepbound into coverage starting in July 2026, the addressable market is expanding rapidly Eli Lilly and company (LLY80). If Lilly continues to execute, the current forward P/E of 33.4x will look like a bargain in hindsight.
Bear Case
The primary risk for Eli Lilly is the "price of confidence." The stock is priced for absolute perfection. As noted by market observers, the market's valuation has moved far beyond current good news, pricing in a future where Lilly executes flawlessly quarter after quarter Eli Lilly Stock And The Price Of Confidence | Trefis.
There are also underlying pricing pressures. Despite massive volume growth, realized prices for Lilly's GLP-1 drugs fell 13% globally in early 2026 as payers pushed back and competition built Eli Lilly (LLY) intrinsic value Analysis by StockOracle™. Furthermore, some conservative analysts, such as Morningstar, maintain a fair value estimate of just $900 per share, citing high uncertainty and the belief that the current stock price overestimates long-term margin sustainability Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? | Morningstar.
Key Metrics Summary
| Metric | July 2026 Data |
|---|---|
| Current Stock Price | ~$1,196.00 |
| LTM Revenue | $86.46 Billion |
| LTM Net Income | $27.58 Billion |
| LTM Diluted EPS | $30.81 |
| Forward P/E | 33.4x |
| PEG Ratio | 1.57 |
| Q1 2026 Revenue Growth | +56% YoY |
| 2026 Revenue Guidance | $85.0B - $87.0B |
Frequently Asked Questions
Is Eli Lilly stock overvalued in 2026?
While traditional value investors might balk at a trailing P/E of 42x, growth investors look at the PEG ratio of 1.57, which factors in the company's massive earnings growth. Compared to peers like Merck (growing at 4.9%), Lilly's 56% growth rate justifies a significant premium. However, conservative models like Morningstar's peg fair value at $900, suggesting some overvaluation risk Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? | Morningstar.
What is driving LLY's revenue growth?
The primary driver is the GLP-1 franchise, specifically Mounjaro (for type 2 diabetes) and Zepbound (for weight loss). In Q1 2026, these two drugs alone generated $12.8 billion in combined revenue, representing the vast majority of the company's top-line expansion Eli Lilly (LLY) intrinsic value Analysis by StockOracle™.
What are the average analyst price targets for LLY?
As of July 2026, major Wall Street firms have price targets ranging from $1,283 (Goldman Sachs) to $1,370 (Truist Securities), implying a 7% to 15% upside from current levels Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades - Benzinga.
How does Eli Lilly compare to Novo Nordisk?
Novo Nordisk trades at a cheaper forward P/E (around 15x) compared to Lilly (33.4x). However, Lilly is growing significantly faster, posting 55.5% revenue growth in recent quarters compared to Novo's 24% Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher - 24/7 Wall St.. Lilly is widely considered to have the best-in-class GLP-1 molecule.
Final Verdict
Recommendation: BUY
Eli Lilly is a generational growth story operating within the defensive healthcare sector. While the stock's valuation leaves little room for macroeconomic missteps or clinical trial failures, the sheer velocity of its revenue and earnings growth cannot be ignored. The company is successfully scaling the most lucrative drug franchise in pharmaceutical history while simultaneously advancing a robust pipeline in Alzheimer's and oncology.
For investors with a long-term horizon, gradually building a position in LLY is a sound strategy. The premium price tag is the cost of admission for owning the undisputed king of the $150 billion weight-loss market.
Reading about a stock concept? Put it into practice on your actual picks.
Enter a ticker for a 10-page institutional-grade research brief: business model, competitive moat, financial health, risks, and a 12-month bull/base/bear scenario.
Watch: Related Videos
from Invest DailyGet This Analysis in Your Inbox Every Morning
Get our daily market briefing with institutional-grade analysis, key developments, and actionable strategy - delivered before the opening bell.
Essential Reading: Top Investor Guides
Our most comprehensive guides - start here to build a complete investing foundation.
Market Basics
Stock Market Fundamentals: How Markets Work, Reading Charts, and Technical Analysis
Portfolio Strategy
Portfolio Management Masterclass: Asset Allocation, Diversification, and Rebalancing
Retirement
The Complete Retirement Planning Guide: 401(k), IRA, Roth, and FIRE Strategy
Dividend Income
The Ultimate Guide to Dividend Investing: How to Build a Safe Income Portfolio
Valuation
The Complete Guide to Stock Valuation: How to Calculate Intrinsic Value
Financial Statements
How to Read a Balance Sheet Like a Professional Analyst
Monetary Policy
Understanding the Federal Reserve: How Monetary Policy Actually Works
Real Estate
Real Estate Investment Trusts (REITs): A Complete Investor's Guide
Options & Hedging
Options Basics: How to Use Derivatives to Protect Your Portfolio
Investor Psychology
